At present, the mainstay of treatment of vasculopathy and autoinflammation phenotypes consists of anti-TNF-agents (etanercept, infliximab, adalimumab) with impressive reductions in stroke incidence (14, 15). The gene discussed is TNF; the disease is vascular disorder.